Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form

Clinical Chemistry

Volumn 52, Issue 1, 2006, Pages 82-87

  Brandt, Inger ^a   Lambeir, Anne Marie ^a   Ketelslegers, Jean Marie ^b   Vanderheyden, Marc ^c   Scharpé, Simon ^a   De Meester, Ingrid ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c CARDIOVASCULAR CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE[1-32]; BRAIN NATRIURETIC PEPTIDE[3-32]; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV; EDETIC ACID; MEMBRANE METALLOENDOPEPTIDASE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; EX VIVO STUDY; HUMAN; HYDROLYSIS; IN VITRO STUDY; MASS SPECTROMETRY; PLASMA; PROTEIN DEGRADATION; PROTEIN MODIFICATION;

ADAMANTANE; ANTIGENS, CD26; ATRIAL NATRIURETIC FACTOR; DIPEPTIDES; HUMANS; HYDROLYSIS; KINETICS; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS;

EID: 29744462729     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.057638     Document Type: Article

References (25)

1. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects [Review]. Eur J Heart Fail 2004;6:261-8.
2. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review [Review]. BMJ 2005;330:625-34.
3. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review [Review]. Clin Chem 2004;50:33-50.
4. de Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in the management of heart failure: the versatile neurohormone [Review]. Chest 2004;125:652-68.
5. Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited [Review]. Clin Chem 2004;50:1503-10.
6. Hall C. Essential biochemistry and physiology of (NT-pro)BNP [Review]. Eur J Heart Fail 2004;6:257-60.
7. Silberbach M, Roberts CT Jr. Natriuretic peptide signalling: molecular and cellular pathways to growth regulation [Review]. Cell Signal 2001;13:221-31.
8. Smith MW, Espiner EA, Yandle TG, Charles CJ, Richards AM. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 2000;167:239-46.
9. Walther T, Stepan H, Pankow K, Becker M, Schultheiss HP, Siems WE. Biochemical analysis of neutral endopeptidase activity reveals independent catabolism of atrial and brain natriuretic peptide. Biol Chem 2004;385:179-84.
10. Ozaki J, Shimizu H, Hashimoto Y, Itoh H, Nakao K, Inui K. Enzymatic inactivation of major circulating forms of atrial and brain natriuretic peptides. Eur J Pharmacol 1999;370:307-12.
11. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide, and some C-receptor ligands by endopeptidase-24. Biochem J 1993;11:291:83-8.
12. Charles CJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG, Protter A, et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol 1996;271:R373-80.
13. Jiang W, Cai DY, Pan CS, Qi YF, Jiang HF, Geng B, et al. Changes in production and metabolism of brain natriuretic peptide in rats with myocardial necrosis. Eur J Pharmacol 2005;507:153-62.
14. Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002;316:129-35.
15. Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV [Review]. Crit Rev Clin Lab Sci 2003;40:209-94.
16. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, et al. 1-{[(3-Hydroxy-1-adamantyl)amino]acetyl}-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl-peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-89.
17. Barlocco D. LAF-237. Curr Opin Investig Drugs 2004;5:1094-100.
18. Brandt I, Joossens J, Chen X, Maes MB, Scharpe S, De Meester I, et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ([2S]-{[(3-hydroxyadamantan-1-yl)amino] acetyl}-pyrrolidine-2- carbonitrile). Biochem Pharmacol 2005;70:134-43.
19. De Meester I, Vanhoof G, Lambeir AM, Scharpé S. Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26/dipeptidyl-peptidase IV (EC 3.4.14.5). J Immunol Methods 1996;189:99-105.
20. Segel IH. Enzyme kinetics, behavior and analysis of rapid equilibrium and steady-state enzyme systems. New York: John Wiley & Sons, 1975:18-89.
21. Schoenfeld JR, Tom JY, Lowe DG. Mutations in B-type natriuretic peptide mediating receptor-A selectivity. FEBS Lett 1997;414:263-7.
22. Schulz-Knappe P, Forssmann K, Herbst F, Hock D, Pipkorn R, Forssmann WG. Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988;6617:752-9.
23. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J, et al. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005;51:486-93.
24. Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005;123:439-45.
25. Vogt-Schaden M, Gagelmann M, Hock D, Herbst F, Forssmann WG. Degradation of porcine brain natriuretic peptide (pBNP-26) by endoprotease-24.11 from kidney cortical membranes. Biochem Biophys Res Commun 1989;161:1177-83.